TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
PRQR

ProQR Therapeutics BV

Healthcare · Biotechnology

1.40$ +8.7% vs. previous close Closing price · As of: Nov 12, 2026

Ownership

Ownership Structure

Who owns ProQR Therapeutics BV (PRQR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 64.8% of the shares are freely tradable; institutional investors hold 42.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 42.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 18.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 64.8%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 2.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 141Mio.

Largest Shareholders

Institutions

Institutions PRQR
Name Stake (%) Shares Change (%) Date
Adage Capital Partners Gp LLC 6.39 9,015,897 +44.2 06/30/2026
Aberdeen Group PLC 6.33 8,932,507 +169.3 06/30/2026
Affinity Asset Advisors, LLC 3.93 5,543,936 +125.9 06/30/2026
Privium Fund Management B.V. 3.91 5,520,024 +1.0 06/30/2026
Ikarian Capital, LLC 2.43 3,425,930 +129.6 06/30/2026
Woodline Partners LP 2.32 3,277,143 +0.0 06/30/2026
Heights Capital Management Inc 1.96 2,762,430 +0.0 06/30/2026
Morgan Stanley - Brokerage Accounts 1.25 1,767,215 +36.0 06/30/2026

Funds

Funds PRQR
Name Stake (%) Shares Change (%) Date
abrdn World Healthcare 4.74 6,684,794 +6.0 09/30/2026
abrdn Life Sciences Investors 2.11 2,982,761 +13.6 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?